MiroBio is a technology company.
MiroBio has raised $130.0M across 2 funding rounds.
MiroBio has raised $130.0M in total across 2 funding rounds.
MiroBio has raised $130.0M in total across 2 funding rounds.
MiroBio's investors include Advent Life Sciences, Atlas Venture, Draper Associates, F-Prime Capital Partners, Global Ventures, Maverick Capital, Novartis Venture Fund, Questa Capital, SR One, Wellington Partners, Curtis Chambers.
MiroBio was a clinical-stage biotechnology company founded in 2019 as a spinout from the University of Oxford, focused on developing checkpoint agonist antibodies to restore immune balance in patients with autoimmune and inflammatory diseases.[2][3][4][5] The company built a proprietary discovery platform called I-ReSToRE (REceptor Selection and Targeting to Reinstate immune Equilibrium), combining antibody engineering with the Checkpoint Atlas receptor mapping tool, to create best-in-class therapeutics targeting immune inhibitory receptors like BTLA and PD-1.[3][4][6] Its lead candidate, MB272 (a BTLA agonist), entered Phase 1 trials in 2022, with additional assets including MB151 (PD-1 agonist) and early-stage programs; MiroBio served the healthcare sector by addressing unmet needs in immune-mediated diseases where current therapies often fail to achieve remission.[2][3][4][7] In August 2022, Gilead Sciences acquired MiroBio for approximately $405 million, integrating its platform and pipeline into Gilead's inflammation R&D strategy.[2][4][6][7]
MiroBio emerged from over 15 years of research in the Oxford University labs of Professor Simon Davis (co-founder) and Professor Richard Cornall, who pioneered agonist antibodies for immune control.[3][5] Spun out in 2019, the company was backed by a £27 million Series A led by Oxford Science Enterprises and Samsara BioCapital, followed by an £80 million Series B in June 2022 led by Medicxi, with Nick Williams joining the board.[6] Early traction came from its I-ReSToRE platform, enabling rapid development of candidates like MB272, which dosed its first patient in Phase 1 shortly before the Gilead acquisition in August 2022—a milestone validating its science just three years post-founding.[2][4][6]
Dr. Carolin Barth served as CEO, leading the team through platform validation and clinical entry.[1]
MiroBio rode the wave of immune modulation innovation, shifting from oncology-focused checkpoint inhibitors to agonists for autoimmune diseases—a trend gaining momentum as biologics dominate inflammation markets amid limitations of small molecules and steroids.[3][6][7] Its 2019 timing capitalized on maturing antibody engineering and Oxford's immunology expertise, aligning with rising venture interest in precision immunology (e.g., Series A/B funding totaling ~$130M).[2][6] Market forces like high autoimmune prevalence and incomplete remission rates with existing therapies (e.g., JAK inhibitors) favored its approach, influencing the ecosystem by validating agonist platforms—now advancing via Gilead, potentially accelerating clinical readouts and inspiring similar spins.[4][6]
Post-acquisition, MiroBio's assets thrive within Gilead's resources, with MB272 likely progressing through Phase 1/2 and I-ReSToRE yielding more candidates like PD-1 agonists over the next few years.[4][7] Trends in personalized immunology and combination therapies will shape its legacy, as big pharma integrates biotech platforms to tackle chronic inflammation. Gilead's commitment signals expanding influence, potentially delivering first-in-class autoimmune treatments and redefining immune balance restoration—echoing MiroBio's founding mission to harness natural controls for patient benefit.[1][4]
MiroBio has raised $130.0M across 2 funding rounds. Most recently, it raised $97.0M Series B in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $97.0M Series B | Advent Life Sciences, Atlas Venture, Draper Associates, F-Prime Capital Partners, Global Ventures, Maverick Capital, Novartis Venture Fund, Questa Capital, SR One, Wellington Partners, Curtis Chambers | |
| Oct 1, 2019 | $33.0M Series A | Advent Life Sciences, Atlas Venture, Draper Associates, F-Prime Capital Partners, Global Ventures, Maverick Capital, Novartis Venture Fund, Questa Capital, SR One, Wellington Partners, Curtis Chambers |